XML 15 R5.htm IDEA: XBRL DOCUMENT v3.21.2
Condensed Consolidated Statements of Changes in Stockholders' Equity (Unaudited) - USD ($)
Preferred Stock
Common Stock
Additional Paid-In Capital
Accumulated Deficit
Total Citius Pharmaceuticals, Inc. Shareholder’s Equity
Non-Controlling Interest
Total
Balance at Sep. 30, 2019 $ 28,930 $ 80,169,724 $ (53,045,782) $ 27,152,872 $ 27,152,872
Balance (in Shares) at Sep. 30, 2019   28,930,493          
Issuance of common stock upon exercise of warrants $ 1,061 (955) 106 106
Issuance of common stock upon exercise of warrants (in Shares)   1,060,615          
Issuance of common stock for services $ 187 99,813 100,000 100,000
Issuance of common stock for services (in Shares)   186,566          
Stock-based compensation expense 220,384 220,384 220,384
Net loss (4,322,370) (4,322,370) (4,322,370)
Balance at Dec. 31, 2019 $ 30,178 80,488,966 (57,368,152) 23,150,992 23,150,992
Balance (in Shares) at Dec. 31, 2019   30,177,674          
Balance at Sep. 30, 2019 $ 28,930 80,169,724 (53,045,782) 27,152,872 27,152,872
Balance (in Shares) at Sep. 30, 2019   28,930,493          
Issuance of common stock for services             428,770
Balance at Jun. 30, 2020 $ 46,316 95,168,985 (66,473,239) 28,742,062 28,742,062
Balance (in Shares) at Jun. 30, 2020   46,316,298          
Balance at Dec. 31, 2019 $ 30,178 80,488,966 (57,368,152) 23,150,992 23,150,992
Balance (in Shares) at Dec. 31, 2019   30,177,674          
Issuance of common stock upon exercise of warrants $ 7,614 6,019,417 6,027,031 6,027,031
Issuance of common stock upon exercise of warrants (in Shares)   7,614,388          
Issuance of common stock for services $ 286 305,734 306,020 306,020
Issuance of common stock for services (in Shares)   286,000          
Stock-based compensation expense 158,833 158,833 158,833
Net loss (4,424,969) (4,424,969) (4,424,969)
Balance at Mar. 31, 2020 $ 38,078 86,972,950 (61,793,121) 25,217,907 25,217,907
Balance (in Shares) at Mar. 31, 2020   38,078,062          
Issuance of common stock in registered direct offering $ 7,059 6,870,041 6,877,100 6,877,100
Issuance of common stock in registered direct offering (in Shares)   7,058,824          
Issuance of common stock upon exercise of warrants $ 1,129 1,128,283 1,129,412 1,129,412
Issuance of common stock upon exercise of warrants (in Shares)   1,129,412          
Issuance of common stock for services $ 50 22,700 22,750 22,750
Issuance of common stock for services (in Shares)   50,000          
Stock-based compensation expense 175,011 175,011 175,011
Net loss (4,680,118) (4,680,118) (4,680,118)
Balance at Jun. 30, 2020 $ 46,316 95,168,985 (66,473,239) 28,742,062 28,742,062
Balance (in Shares) at Jun. 30, 2020   46,316,298          
Balance at Sep. 30, 2020 $ 55,577 104,208,958 (70,593,867) 33,670,668 33,670,668
Balance (in Shares) at Sep. 30, 2020   55,576,996          
Issuance of NoveCite common stock 1,799,640 (2,399,520) (599,880) 600,380 500
Stock-based compensation expense 276,582 276,582 276,582
Net loss (8,146,909) (8,146,909) (8,146,909)
Balance at Dec. 31, 2020 $ 55,577 106,285,180 (81,140,296) 25,200,461 600,380 25,800,841
Balance (in Shares) at Dec. 31, 2020   55,576,996          
Balance at Sep. 30, 2020 $ 55,577 104,208,958 (70,593,867) 33,670,668 33,670,668
Balance (in Shares) at Sep. 30, 2020   55,576,996          
Issuance of common stock for services             68,000
Balance at Jun. 30, 2021 $ 145,979 227,622,330 (91,086,736) 136,681,573 600,380 137,281,953
Balance (in Shares) at Jun. 30, 2021   145,979,429          
Balance at Dec. 31, 2020 $ 55,577 106,285,180 (81,140,296) 25,200,461 600,380 25,800,841
Balance (in Shares) at Dec. 31, 2020   55,576,996          
Issuance of common stock in private placement offering $ 15,456 18,434,954 18,450,410 18,450,410
Issuance of common stock in private placement offering (in Shares)   15,455,960          
Issuance of common stock in registered direct offering $ 50,830 70,929,012 70,979,842 70,979,842
Issuance of common stock in registered direct offering (in Shares)   50,830,566          
Issuance of common stock upon exercise of warrants $ 12,788 14,229,755 14,242,543 14,242,543
Issuance of common stock upon exercise of warrants (in Shares)   12,787,697          
Issuance of common stock for services $ 50 67,950 68,000 68,000
Issuance of common stock for services (in Shares)   50,000          
Stock-based compensation expense 342,962 342,962 342,962
Net loss (4,122,432) (4,122,432) (4,122,432)
Balance at Mar. 31, 2021 $ 134,701 210,289,813 (85,262,728) 125,161,786 600,380 125,762,166
Balance (in Shares) at Mar. 31, 2021   134,701,219          
Issuance of common stock upon exercise of warrants $ 11,208 16,876,383 16,887,591 16,887,591
Issuance of common stock upon exercise of warrants (in Shares)   11,208,210          
Issuance of common stock upon exercise of stock options $ 70 82,564 82,634 82,634
Issuance of common stock upon exercise of stock options (in Shares)   70,000          
Stock-based compensation expense 373,570 373,570 373,570
Net loss (5,824,008) (5,824,008) (5,824,008)
Balance at Jun. 30, 2021 $ 145,979 $ 227,622,330 $ (91,086,736) $ 136,681,573 $ 600,380 $ 137,281,953
Balance (in Shares) at Jun. 30, 2021   145,979,429